4 burning questions about Amgen's obesity drug

Taking stock of the drug industry, from the lab to the medicine chest

May 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark J. Terrill/AP STAT+ | 4 burning questions about Amgen's obesity drug, a potential Wegovy and Zepbound competitor Heavy Wall Street interest in potential competition to Wegovy, from Novo Nordisk, and Zepbound, from Eli Lilly, as plans are made for broad Phase 3 trials. By Elaine Chen STAT+ | Senate drug shortage bill would pay hospitals bonuses for good contracting practices This bill is the first to propose that Medicare pay bonuses to hospitals and physicians for contracting practices that avoid drug shortages. By John Wilkerson STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser